Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.05 and traded as high as $0.06. Nascent Biotech shares last traded at $0.06, with a volume of 79,091 shares trading hands.
Nascent Biotech Stock Down 8.3 %
The stock has a fifty day moving average price of $0.05 and a 200-day moving average price of $0.07.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Featured Stories
- Five stocks we like better than Nascent Biotech
- Following Congress Stock Trades
- Texas Roadhouse Stock Steering for New Highs This Year
- Stock Average Calculator
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Is WallStreetBets and What Stocks Are They Targeting?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
